Compare Citius Pharmaceuticals Inc (CTXR) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Suncor Energy Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Suncor Energy Inc. trades at $63.2 (market cap $73.34B). The key difference: Suncor Energy Inc. is far larger — about 3915.6× Citius Pharmaceuticals Inc's market cap, and Suncor Energy Inc. pays a 2.72% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SU | |
|---|---|---|
Market Cap | $18.73M | $73.34B |
Sector | Health | Energy |
52-Week High | $1.82 | $69.73 |
52-Week Low | $0.48 | $38.17 |
Enterprise Value | $14.95M | $80.01B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Suncor Energy (SU) trades at $60.1, down 2.04% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $2.27, beating estimates, and maintains a strong balance sheet with $3.48B in cash. Valuation ratios appear attractive with a P/E of 11.24 and EV/EBITDA of 5.42. Recent news highlights leadership changes, with Peter Zebedee set to become CEO in 2027.
Outlook is mixed: strong cash flow and analyst buy ratings (74% consensus) support upside, but near-term technical weakness and operational challenges from weather impacts pose risks. The stock offers value with solid profitability (ROE 19.25%) but faces volatility from oil price fluctuations and execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
